AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:06 2024-06-21 am EDT 5-day change 1st Jan Change
12,472 GBX +0.60% Intraday chart for AstraZeneca PLC -0.30% +17.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US FDA approves Roche's drug for a chronic blood disorder RE
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
AstraZeneca Says Truqap With Faslodex Combination Approved in EU for Breast Cancer MT
AstraZeneca's Truqap gets OK from EU for breast cancer form AN
AstraZeneca: EU approval in breast cancer CF
AstraZeneca Wins EU Approval for Breast Cancer Combination Treatment MT
Astrazeneca Says Truqap Plus Faslodex Approved In EU RE
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients MT
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... Our Logo
ASTRAZENECA : Goldman Sachs maintains a Buy rating ZD
AstraZeneca plc Updates on the CAPItello-290 Phase III Trial for Truqap Plus Chemotherapy CI
AstraZeneca disappointed by breast cancer drug trial results AN
London follows US bullish trend Our Logo
AstraZeneca: inconclusive trial in breast cancer CF
AstraZeneca's Breast Cancer Combo Fails to Extend Overall Survival in Late-stage Trial MT
UK Stocks-Factors to watch on June 18 RE
Ashtead profit declines; Whitbread sales rise AN
AstraZeneca's breast cancer drug combination fails in late-stage trial RE
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals DJ
European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov MT
Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco... Our Logo
AstraZeneca Says FDA Approves Imfinzi to Treat Endometrial Cancer MT
AstraZeneca: positive phase 3 results in lymphoma CF
AstraZeneca's Blood Cancer Combination Therapy Meets Primary Goal in Late-Stage Study MT
London stocks rebound ahead of key Economic data Our Logo
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5 USD
Average target price
174.4 USD
Spread / Average Target
+10.77%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%